NCT00337129 · OUTCOME
Overall Survival
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEDIAN
- Unit
- months
- Interval / dispersion
- 95% Confidence Interval
- Time frame
- Every 3 months for first year, then every six months thereafter up to a maximum of 3 years from registration.
What was measured
Overall survival was defined as the time from the date of registration to the date of death due to any cause. Patients last known to be alive are censored at date of last contact.
Analysis population: Only eligible patients were included in the analysis.
Groups in this outcome
Treatment (E7389 IV)
Patients receive E7389 IV on days 1 and 8 of an every 21-day cycle.
| Group | Source count |
|---|---|
| Treatment (E7389 IV) | 40 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Treatment (E7389 IV) | 7 | Not reported | 5 | 10 | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- lower Limit
- 5
- upper Limit
- 10
- value
- 7
- denoms
- counts
- group Id
- OG000
- value
- 40
- units
- Participants
- description
- Overall survival was defined as the time from the date of registration to the date of death due to any cause. Patients last known to be alive are censored at date of last contact.
- dispersion Type
- 95% Confidence Interval
- groups
- description
- Patients receive E7389 IV on days 1 and 8 of an every 21-day cycle.
- id
- OG000
- title
- Treatment (E7389 IV)
- param Type
- MEDIAN
- population Description
- Only eligible patients were included in the analysis.
- reporting Status
- POSTED
- time Frame
- Every 3 months for first year, then every six months thereafter up to a maximum of 3 years from registration.
- title
- Overall Survival
- type
- SECONDARY
- unit Of Measure
- months
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle